Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial

Fig. 1

Endothelial progenitor (CD34+), CD34+ CD184+ cell expression and Migration. Flow cytometry-based assay for CD34positive cells and CD34+ CD184 dual positive cells. a Mean CD34 cell number increased in Linagliptin group from visit 1 to 3. b The functional improvement of CD34+ cells can be further supported by statistically significant expression of CD34+ CD184 dual positive cells (CXCR4) (p < 0.02) measured by flow cytometry. Interesting pattern can be appreciated here, as double positivity dropped from visit 1 to 2 in the placebo group but in Linagliptin group it went up, though the graphs merged at visit 3. c The mean fluorescence intensities (normalized to control samples) is shown here. A trend in increased migratory response of CD34+ve cells to the chemotactic factor SDF1α(100 ng/ml) is observed in linagliptin group at visit 3

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840